The use of targeted radionuclide therapy for the treatment of malignant melanoma in vivo

Joyce, C. and Boyd, M. and Sorensen, A. and Tesson, M. and Babich, J. W. and Mairs, R. J. (2012) The use of targeted radionuclide therapy for the treatment of malignant melanoma in vivo. Mutagenesis, 27 (1). p. 110. ISSN 0267-8357 (https://doi.org/10.1093/mutage/ger068)

Abstract

This study investigates the potential of the noradrenaline analogue [131I]MIBG (metaiodobenzylguanidine) and the novel melanin binding benzamide [131I] Solazed for melanoma therapy in vivo and in vitro.

ORCID iDs

Boyd, M. ORCID: https://orcid.org/0000-0003-4120-2218

Sorensen, A. ORCID: https://orcid.org/0000-0002-1861-7258

• Share and Export
  

  RDF+XMLBibTeXRIOXX2 XMLRDF+N-TriplesJSONDublin CoreAtomSimple MetadataReferMETSHTML CitationASCII CitationOpenURL ContextObjectEndNoteOpenURL ContextObject in SpanMODSMPEG-21 DIDLEP3 XMLData Cite XMLRIS (EndNote Online, Zotero, Ref manager, etc)RDF+N3Multiline CSV
• Citations and altmetrics
• Item metadata

  Item type:	Article
  ID code:	40173
  Dates:	Date Event January 2012 Published
  Keywords:	targeted radionuclide therapy, treatment, malignant melanoma , in vivo, in vitro, noradrenaline analogue , metaiodobenzylguanidine, Pharmacy and materia medica, Genetics, Genetics(clinical), Health, Toxicology and Mutagenesis, Toxicology
  Subjects:	Medicine > Pharmacy and materia medica
  Department:	Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Technology and Innovation Centre > Advanced Science and Technology Technology and Innovation Centre > Bionanotechnology
  Depositing user:	Pure Administrator
  Date deposited:	22 Jun 2012 11:06
  Last modified:	18 Jan 2023 09:23
  URI:	https://strathprints.strath.ac.uk/id/eprint/40173